PMID- 37448470
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230918
IS  - 1179-5549 (Print)
IS  - 1179-5549 (Electronic)
IS  - 1179-5549 (Linking)
VI  - 17
DP  - 2023
TI  - A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in 
      Chinese Patients With Breast Cancer.
PG  - 11795549231182266
LID - 10.1177/11795549231182266 [doi]
LID - 11795549231182266
AB  - BACKGROUND: Denosumab entered the Chinese market for the first time in 2020. 
      Since it is a short period of time, there is a lack of data on its effectiveness 
      and safety in Chinese people. The objective of this study was to evaluate the 
      effectiveness and safety of denosumab in delaying skeletal-related events (SREs) 
      in patients with breast cancer metastatic to bone. METHODS: The study 
      retrospectively analyzed data from breast cancer patients with bone metastases 
      (BM) who were treated with denosumab in the First Affiliated Hospital of Nanjing 
      Medical University from September 2020 to January 2022. The primary endpoint was 
      SRE incidence at 1 year after receiving denosumab treatment. The secondary 
      endpoints included time to first on-study SRE and safety. Descriptive analysis 
      was utilized to display clinicopathological features. The Kaplan-Meier method was 
      used to estimate the median time to first on-study SRE in total population and 
      subgroups. Logistic regression analysis and chi(2) test were employed to determine 
      the potential factors influencing the occurrence of SREs. RESULTS: Fifty breast 
      cancer patients with BM were enrolled in our study, and 54.0% of the patients had 
      5 or more metastatic bone lesions. After a median follow-up of 17.00 months, 24% 
      of the patients developed SREs at 1 year after receiving denosumab treatment, and 
      the median time to first on-study SREs was not reached. Five or more metastatic 
      bone lesions were an independent risk factor for SRE occurrence (odds 
      ratio = 6.06, 95% CI: 1.09-33.54, P = .039). The adverse events (AEs) associated 
      with denosumab mainly included hypocalcemia (68.0%), periodontitis (28.0%), and 
      myalgia (14.0%). Only 3 cases of grade III/IV AEs were reported, and no serious 
      AEs occurred. CONCLUSION: Denosumab was effective and well tolerated in Chinese 
      breast cancer patients with BM.
CI  - (c) The Author(s) 2023.
FAU - Li, Wei
AU  - Li W
AUID- ORCID: 0000-0001-5950-3161
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
AD  - Department of Medicine, Nanjing Medical University, Nanjing, China.
FAU - Wu, Xinyu
AU  - Wu X
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
AD  - Department of Medicine, Nanjing Medical University, Nanjing, China.
FAU - Yu, Heng
AU  - Yu H
AD  - Department of Medicine, Nanjing Medical University, Nanjing, China.
FAU - Zhu, Zekai
AU  - Zhu Z
AD  - Department of Medicine, Nanjing Medical University, Nanjing, China.
FAU - Li, Wenjie
AU  - Li W
AD  - Department of Medicine, Nanjing Medical University, Nanjing, China.
FAU - Huang, Xiang
AU  - Huang X
AUID- ORCID: 0000-0002-7448-1711
AD  - Department of Oncology, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20230710
PL  - United States
TA  - Clin Med Insights Oncol
JT  - Clinical Medicine Insights. Oncology
JID - 101525771
PMC - PMC10336762
OTO - NOTNLM
OT  - Breast cancer
OT  - bone metastasis
OT  - bone-modifying agents
OT  - denosumab
OT  - skeletal related events
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/07/14 13:07
MHDA- 2023/07/14 13:08
PMCR- 2023/07/10
CRDT- 2023/07/14 03:45
PHST- 2023/02/04 00:00 [received]
PHST- 2023/05/29 00:00 [accepted]
PHST- 2023/07/14 13:07 [pubmed]
PHST- 2023/07/14 13:08 [medline]
PHST- 2023/07/14 03:45 [entrez]
PHST- 2023/07/10 00:00 [pmc-release]
AID - 10.1177_11795549231182266 [pii]
AID - 10.1177/11795549231182266 [doi]
PST - epublish
SO  - Clin Med Insights Oncol. 2023 Jul 10;17:11795549231182266. doi: 
      10.1177/11795549231182266. eCollection 2023.